Use of ultralow doses of antibodies to gamma-interferon in the treatment and prophylaxis of viral infections

Viral infections are at present the leading cause of morbidity in the world. The clinical trials of gamma-anaferon (pediatric formulation) in the treatment and prophylaxis of a great number of viral infections (more than 20 nosological forms) due to the RNA- and DNA-containing viruses demonstrated i...

Full description

Saved in:
Bibliographic Details
Published inAntibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] Vol. 53; no. 3-4; p. 32
Main Authors Vasil'ev, A N, Sergeeva, S A, Kachanova, M V, Tarasov, S A, Elfimova, U V, Dugina, Iu L, Epshteĭn, O I
Format Journal Article
LanguageRussian
Published Russia (Federation) 2008
Subjects
Adolescent
Adult
Antibodies - administration & dosage
Antibodies - immunology
Child
Child, Preschool
Female
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - immunology
Infant
Infant, Newborn
Interferon-gamma - immunology
Male
Virus Diseases - immunology
Virus Diseases - prevention & control
Online AccessGet more information

Cover

More Information
Summary:Viral infections are at present the leading cause of morbidity in the world. The clinical trials of gamma-anaferon (pediatric formulation) in the treatment and prophylaxis of a great number of viral infections (more than 20 nosological forms) due to the RNA- and DNA-containing viruses demonstrated its efficacy and safety. Gamma-anaferon is an immunomodulator with antiviral activity containing ultralow doses of antibodies to interferon. The high efficacy of anaferon and no adverse effects allowed to consider it as the drug of choice in the treatment of various viral infections including those in children under 1 year.
ISSN:0235-2990